MedTrace Logo

NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors

NCT01324115 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2015-03-05

No results posted yet for this study

Summary

RATIONALE: NG-nitro-L-arginine may stop the growth of tumor cells by disrupting blood flow to the tumor.

PURPOSE: This phase I trial is studying the side effects and best dose of NG-nitro-L-arginine in treating patients with advanced solid tumors.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

NG-nitro-L-arginine

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

computed tomography

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Sponsors & Collaborators

Principal Investigators

  • Peter J. Hoskin, MD · Mount Vernon Cancer Centre at Mount Vernon Hospital

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01324115 on ClinicalTrials.gov